Oral sophocarpine protects rat heart against pressure overload-induced cardiac fibrosis
Authors:
- 20 February 2014
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 52 (8) , 1045-1051
Abstract
Context: Sophocarpine, a tetracyclic quinolizidine alkaloid, is one of the most abundant active ingredients in Sophora alopecuroides Linn. (Kudouzi). Sophocarpine injection was found to have significant antiviral effects against coxsackievirus B3 and therapeutic effects for viral myocarditis in the clinic. Objective: This study assessed the effects of sophocapine on overload-induced cardiac fibrosis and investigated potential mechanisms. Materials and methods: Adult male Sprague–Dawley rats were subjected to a suprarenal abdominal aorta constriction (AC) or sham to induce sustained pressure overload. Six weeks later, rats were randomly assigned to receive sophocapine (10, 20, and 40 mg/kg, gavage) or vehicle treatment for an additional 6 weeks. Six weeks after treatment, cardiac dysfunction, cardiac coefficient, cardiac fibrosis, hydroxyproline concentration, and inflammation mediators were examined. Results: When compared with the model group, the left ventricular weight/body weight decreased by 25.4% and 39.0% in 20 and 40 mg/kg sophocarpine groups, respectively. The beneficial effects were associated with amelioration of left ventricular systolic pressure (LVSP) and left ventricular enddiastolic pressure (LVEDP). Moreover, pressure overload-induced cardiac fibrosis was attenuated in sophocarpine treated groups. Importantly, sophocarpine (20 and 40 mg/kg) decreased pro-inflammatory cytokine levels (IL-6, 14.6% and 18.5%; IL-1β, 23.1% and 32.6%), collagen content (27.7% and 50.1%), as well as matrix metalloproteinases-2, 9 (MMP-2, 9) expression (MMP-2, 11.8% and 18.5%; MMP-9, 16.2% and 21.1%). Sophocarpine (40 mg/kg) inhibited IκB-α phosphorylation (19.0%). Conclusion: These findings indicated that sophocarpine potentially had antifibrotic effects. The mechanism might be due to modulation of the balance between pro-inflammatory cytokine expression and collagen content level as well as MMPs expression via the NF-κB signaling pathway.Keywords
This publication has 24 references indexed in Scilit:
- Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathyHeart, 2012
- Artemisinin Attenuates Post-Infarct Myocardial Remodeling by Down-Regulating the NF-κB PathwayThe Tohoku Journal of Experimental Medicine, 2012
- Monitoring cardiac fibrosis: a technical challengeNetherlands Heart Journal, 2011
- Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinasesExperimental Physiology, 2011
- Exaggerated Blood Pressure Variability Superimposed on Hypertension Aggravates Cardiac Remodeling in Rats via Angiotensin II System-Mediated Chronic InflammationHypertension, 2009
- Anti-nociceptive and anti-inflammatory activity of sophocarpineJournal of Ethnopharmacology, 2009
- Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-κB nuclear translocation and Iκ-B phosphorylation in RAW 264.7 macrophage cellsMolecular Immunology, 2007
- Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in ratsJournal of Veterinary Science, 2007
- Review of Trials in Chronic Heart Failure Showing Broad-Spectrum Anti-Inflammatory ApproachesThe American Journal of Cardiology, 2005
- Hypertensive Myocardial Fibrosis and Diastolic DysfunctionHypertension, 2004